FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/18/2025
Back to search
Official data from USPTO
XPLAZO
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
12/19/2025
Trademark type
Word
Nice classes
5
Filing date
09/01/2023
Registration date
12/03/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/03/2024
Last transaction
12/19/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
25
Owner location
CH
Examiner
PARKS,KIMBERLY L
Law office
M30
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
CSL Behring AG
Representatives
Scott D. Woldow Smith, Gambrell & Russell, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for cardiovascular diseasesillnessesconditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditionsnovelplasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular eventsMACEin patients within 90 days of an acute myocardial infarctionAMIwith a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarctionAMIPharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand diseasehemophiliaprimary immunodeficiencyhereditary angioedemafibrinogen deficiencyAlpha 1 antitrypsin deficiencyinflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophiliapharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditionsrespiratory conditionspneumoniacovid-19influenza; Pharmaceutical preparationsantibody for the treatment of acute respiratory distress syndromeARDS; pharmaceutical preparationsantibody for the treatment of Idiopathic Pulmonary FibrosisIPF and Interstitial Lung DiseasesILD; Pharmaceutical preparationsantibody for the treatment of Hereditary AngioedemaHAE; Pharmaceutical preparationsfor the treatment of Hereditary AngioedemaHAErespiratory diseasesacute respiratory distress syndromeARDSIdiopathic Pulmonary FibrosisIPF and Interstitial Lung DiseasesILD
Publications
History of USPTO decisions and trademark events.
22 publications found
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
11/13/2025
XXCR
GENERIC MADRID TRANSACTION CREATED
11/13/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/03/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
12/03/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/01/2024
PUBO
PUBLISHED FOR OPPOSITION
10/01/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/11/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/26/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/26/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/26/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/26/2024
RFNP
REFUSAL PROCESSED BY IB
06/11/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/15/2024
RFRR
REFUSAL PROCESSED BY MPU
05/15/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/07/2024
CNRT
NON-FINAL ACTION WRITTEN
05/06/2024
DOCK
ASSIGNED TO EXAMINER
04/30/2024
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
02/14/2024
MAFR
APPLICATION FILING RECEIPT MAILED
10/24/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/20/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/19/2023
Continuous trademark protection
Get notified about every new filing that threatens XPLAZO or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.